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ABSTRACT 
Periodontitis is an inflammatory response to the overgrowth of anaerobic organisms in the sub gingiva and if unchecked, results in the destruction of the bone 
and soft tissues supporting the tooth. Studies suggest that clarithromycin can attain higher concentration in the inflammed gingiva and it also produces anti-
inflammatory effect. The systemic drug administration has been useful in treating periodontitis but the disadvantage that, the drug is diluted several thousand 
folds before it reaches the site. This problem can be overcome by administering the drug directly to the intended site of action with lesser dose. In present 
study periodontal strips were prepared by using solvent casting technique. Formulations were designed by taking Ethyl cellulose alone and with copolymers 
(HPMC  K4M,  Eudragit  RS‐  100,  PVP  K30)  was  dissolved  in  chloroform  and  dichloromethane  (1:1)  solution,  using  dibutyl  phthalate  and  PEG‐400 as 
plasticizers. 
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INTRODUCTION 
Periodontitis is an inflammatory response to the overgrowth 
of anaerobic organisms in the sub gingiva and if unchecked, 
results  in  the  destruction  of  the  bone  and  soft  tissues 
supporting  the  tooth.
1,2  The  bacterial  toxins  and  certain 
enzymes produced by the body to fight the infection actually 
breaks down the bone and the connective tissue holding the 
teeth. Periodontitis is characterized by the inflammation of 
gingiva followed by the formation of periodontal pocket and 
absorption of the alveolar bone. This results in the loosening 
of  the  tooth.  Conventionally  scaling,  root  planning  and 
surgical procedures were proposed to treat the periodontitis. 
But due to the mechanical limitations and the inefficacy of 
these  procedures,  use  of  antibiotics  in  conjunction  to  the 
conventional  therapy  is  proposed.  Clarithromycin  is 
chemically  6-O-methylerythromycin.  It  is  a  semi  synthetic 
broad  spectrum  macrolide  antibiotic  with  a  biological  half 
life  of  3  –  4  hours.  The  main  adverse  effects  of 
clarithromycin  are  diarrhoea,  nausea,  vomiting  and 
dyspepsia.  It  is  available  in  the  market  as  conventional 
dosage forms such as tablets, capsules, and parenterals for the 
treatment of bacterial infections but not present as controlled 
dosage form for the treatment of infection locally.  
Studies  suggests  that  clarithromycin  can  attain  higher 
concentration in the inflammed gingiva and it also produces 
anti-inflammatory effect.
3  The systemic drug administration 
has been useful in treating periodontitis but the disadvantage 
that,  the  drug  is  diluted  several  thousand  folds  before  it 
reaches the site and exposes the rest of the body to potential 
side effects. This problem can be overcome by administering 
the  drug  directly  to  the  intended  site  of  action  with lesser 
dose.  In  the  context  to  above  mentioned  principles 
clarithromycin  is  chosen  as  a  model  drug  for  the  present 
study.  The  purpose  of  the  present  study  is  to  formulate 
periodontal  strips,  which  could  be  easily  placed  into  the 
periodontal pocket, and be capable of delivering therapeutic 
concentration of clarithromycin for prolonged period of time 
with  a  much  lower  dose,  hence  obviating  untoward  side 
effects. 
MATERIALS AND METHODS 
Clarithromycin  was  obtained  as  gift  sample  from  Regain 
Laboratories  Pvt.  Ltd.,  Hissar.  Hydroxy  propyl  Methyl 
Cellulose  (HPMC  K4M),  Eudragit  RS  100,  Poly-vinyl-
pyrrolidine K30 (PVP K30), PEG 400 were obtained from 
CDH  Pvt.  Ltd,  New  Delhi.  All  other reagents and  solvent 
used were of analytical grade. 
PREPARATION  OF  CAST  STRIPS  CONTAINING 
CLARITHROMYCIN 
Periodontal  strips  were  prepared  by  using  solvent  casting 
technique. For the purpose glass moulds of area 15cm
2 were 
used. Formulations were designed as shown in table 1. Ethyl 
cellulose alone and with copolymers (HPMC K4M, Eudragit 
RS  100  and  PVP  K‐30)  was  dissolved  in  chloroform  and 
dichloromethane (1:1) solution, using dibutyl phthalate and 
PEG‐400 as plasticizers. Clarithromycin was added into the 
polymeric mixture and mixed homogenously using magnetic 
stirrer in a closed beaker. After complete mixing the solution 
was kept aside to remove entrapped air bubbles. The solution 
was  then  taken  and  poured  into  the  clean  leveled  glass 
moulds.  The  solvent  was  allowed  to  evaporate  slowly  by 
inverting a glass funnel with a cotton plug closed into the 
stem of the funnel at room temperature for 24 hours. After 
complete  evaporation of solvent, cast strips were obtained, 
which were then cut into pieces of 7×4 mm, wrapped in an 
aluminum foil and stored in a desiccator at room temperature 
in a dark place for further evaluation studies.  
EVALUATION  OF  THE  PREPARED 
FORMULATIONS: 
Uniformity of Thickness: Five   strips   were   taken   from  
each  batch  and  their  individual  thickness  was measured 
using micrometer screw gauge. 
Uniformity of Weight: Five  strips  were  taken  from  each  
batch   and   their   individual  weights   were determined by 
using electronic balance. 
Uniformity of Drug Content: Five  strips  were taken from 
each batch and individually dissolved in 5 ml of phosphate 
buffer pH 6.8 solution in a beaker and filter it. 0.2 ml of the 
filtered solution was diluted  to  10ml with chloroform in a 
volumetric  flask.  To  this  10ml  of  solution  taken  in  a 
separating funnel 5ml of conc. HCl was added followed by 
the addition of 10ml of acetone, was shaken for 5 mins. for 
the formation of stable coloured complex. The upper orange-
red coloured layer was separated out and the absorbance was 
measured using UV-Vis spectrophotometer at λ max 487 nm. Kothari Sudeep et al. IRJP 2012, 3 (8) 
Page 266 
Tensile Strength of the Strips: Tensile strength of the strips 
was  determined  by  Universal  strength  testing  machine.  It 
consists of two load cell grips, the lower one is fixed and 
upper one is movable. The test strip of specific size (4 × 2 
cm)  was  fixed  between  these  cell  grips  and  force  was 
gradually applied till the strip breaks. The tensile strength of 
the  strip  was  taken  directly  from  the  dial  reading  in 
kilograms. 
Folding  Endurance:  The  folding  endurance  of  the  strips 
was determined by repeatedly folding the strip at the same 
place  up  to  300  times  till  it  broke  or  folded,  which  is 
considered satisfactory to reveal good strip properties. This 
test was carried out on all the strips.
4 
In vitro Drug Release: Static dissolution method reported in 
the  literature  was  adopted.  Strips  of  known  weight  and 
dimensions (size of 7×4 mm) were placed separately into 6 
sets of small test tubes containing 2 ml of pH 6.8 phosphate 
buffer. The test tubes were sealed with aluminum foil and 
kept at 37°C for 24 hours. 1 ml of buffer was taken out and 
replaced with fresh 1 ml of pH 6.8 phosphate buffer after 
every 24 hours. The concentration of drug in this 1 ml of 
buffer was measured using UV-Vis spectrophotometer at λ 
max 487 nm. The procedure was repeated for 8 days.
5, 6 
RESULTS AND DISCUSSION:- 
Periodontal  strips  were  prepared  by  using  solvent  casting 
technique. Formulations were designed as shown in table I. 
Ethyl  cellulose  alone  and  with  copolymers  (HPMC  K4M, 
Eudragit  RS‐  100,  PVP  K30)  was  dissolved  in  chloroform 
and dichloromethane (1:1) solution, using dibutyl phthalate 
and PEG‐400 as plasticizers. 
The weight of all the strips was found to be in the range of 
9.8 ± 0.064 to 10.7 ± 0.008. The uniformity of weight of the 
strip  indicates  good  distribution  of  the  drug,  polymer  and 
plasticizer.  The  physicochemical  evaluation  data  for 
uniformity of weight and thickness is presented in table II. 
The prepared strips were evaluated for the thickness using 
micrometer screw gauge. The average of three readings was 
taken;  the  mean  thickness  and  standard  deviation  were 
calculated.  The  low  standard  deviation  of  the  measured 
thickness  of  all  the  4  formulations  may  indicate  uniform 
distribution of drug and excipients in prepared implants. It 
was found to be in the range of 0.415 ± 0.026 to 0.451 ± 
0.008.  
For various formulations, the % drug content was found to 
vary  between  91.31  ±  0.022  to  %  96.76  ±  0.034.  Tensile 
strength was found to range between 1.54 ± 0.056 to 1.88 ± 
0.028. Folding endurance values ranged from 188.33 ± 0.57 
to 214.33 ± 1.52.  
The release profile of the formulations is shown in the figure 
I.  The  periodontal  implants  prepared  with  Ethyl  cellulose 
(F1) releases the drug completely in 6 days. The release of 
the drug from the formulation F1 was found to be 94.36% at 
the end of 6 days. The formulation with Ethyl cellulose and 
HPMC K4M (F2) showed complete release in 4 days.  
The release  of  drug  from  formulation  F2  was  found  to  be 
93.91%  at  the  end  of  4  days.  The  formulation  with  Ethyl 
cellulose and PVP K30 (F3) showed complete release in 7 
days. The release of drug from formulation F3 was found to 
be 95.12% at the end of 7 days. The formulation with Ethyl 
cellulose and Eudragit RS 100 (F4) showed complete release 
in 8 days. The release of drug from formulation F4 was found 
to be 98.66% at the end of 8 days. 
In vitro release studies shows that the drug release was more 
sustained in case of strip F4 followed by F3 > F1 > F2. The 
regression values of strips F1 to F4 are higher with first order 
and therefore the release kinetics followed first order from all 
the strips. The release data of clarithromycin strips (F1 to F4) 
were given in table IV and fig II & III.  
Hixson  Crowell  cube  root  law  and  Higuchi’s  model  were 
applied  to  test  the  release  mechanism.  The  R
2  values  are 
higher  for  Higuchi’s  model  compared  to  Hixson  Crowell 
cube root law for all the strips. Hence clarithromycin release 
from  all  the  strips  followed  diffusion  rate  controlled 
mechanism as shown in table IV.  
CONCLUSION 
Various  batches  of  Clarithromycin  periodontal  strips  were 
prepared by solvent casting method and characterized. The 
formulations  F3  (Clarithromycin,  Ethyl  cellulose  and  PVP 
K30) and F4 (Clarithromycin, Ethyl cellulose and Eudragit 
RS 100) satisfied required pharmaceutical characteristics of 
periodontal  implant  and  was  found  promising.  The 
Clarithromycin periodontal implants would be able to offer 
benefits such as increasing residence time, prolonging drug 
release,  reducing  frequency  of  administration,  and  thereby 
may help to improve patient compliance. The results indicate 
formulation  F3  and  F4  has  better  drug  release  over  an 
extended period of 7 and 8 days respectively. 
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Table I. Composition of Different Clarithromycin Periodontal Strips 
Ingredients  F1  F2  F3  F4 
Drug (mg)  120  120  120  120 
Ethyl Cellulose (mg)  1200  1000  1000  1000 
HPMC K4M(mg)  -  200  -  - 
PVP K30(g)  -  -  200  - 
Eudragit RS 100 (mg)  -  -  -  200 
Dibutyl phthalate (ml)  0.3  0.3  0.3  0.3 
PEG 400 (ml)  0.1  0.1  0.1  0.1 
 
Table II. Physicochemical characteristics of strips containing Clarithromycin 
Strips  Weight 
(mg) ± SD 
Thickness (mm) ± 
SD 
Tensile strength  
(kg) ± SD 
Drug content % ± 
SD 
Folding Endurance 
 
F1 
 
10.5 ± 0.042 
 
0.427 ± 0.024 
 
1.32 ± 0.032 
 
93.56 ± 0.062 
 
198.33 ± 1.52 
 
F2 
 
9.8 ± 0.064 
 
0.415 ± 0.026 
 
1.54 ± 0.056 
 
91.31 ± 0.022 
 
188.33 ± 0.57 
 
F3 
 
10.1 ± 0.032 
 
0.451 ± 0.008 
 
1.51 ± 0.016 
 
94.54 ± 0.024 
 
214.33 ± 1.52 
 
F4 
 
10.7 ± 0.008 
 
0.449 ± 0.036 
 
1.88 ± 0.028 
 
96.76 ± 0.034 
 
210.33 ± 0.57 Kothari Sudeep et al. IRJP 2012, 3 (8) 
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Table III. In vitro release profile of Clarithromycin strips. 
Time 
(Days) 
% Drug Release 
F1  F2  F3  F4 
0  0  0  0  0 
1  31.27  38.21  34.69  33.46 
2  54.31  63.29  51.24  53.44 
3  72.17  82.99  68.53  66.25 
4  79.11  93.91  76.71  77.09 
5  88.69  -  86.58  89.65 
6  94.36  -  90.88  92.93 
7  -  -  95.12  96.16 
8  -  -  -  98.66 
 
Table IV. Comparison of R
2 values for F1-F4. 
Strip Code  Regression Coefficient (R
2) Values 
Zero Order  First Order  Higuchi’s Model  Hixson- Crowell Model 
F1  0.892  0.9385  0.9956  0.9704 
F2  0.7877  0.981  0.9652  0.9438 
F3  0.8513  0.9598  0.9816  0.9744 
F4  0.8288  0.9184  0.9816  0.9744 
 
 
 
Fig I. In vitro release profile of Clarithromycin strips 
 
 
Fig. II. Zero order release profile of F1-F4 
 
 
Fig. III. First order release profile of F1-F4 
 
 
 
Fig. IV. Higuchi’s model for F1-F4 
 
 
Fig. V. Hixson-Crowell model for F1-F4 
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